Emilie Da Costa Branquinho

Emilie Da Costa Branquinho

Auto-generated profile, based on publicly available information

Emilie Da Costa Branquinho

Department of Radio‐pharmacology Institut Curie Site Saint‐Cloud Saint‐Cloud France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2015 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
KOKillian Oukoloff
Killian Oukoloff
MBMonika BOUET
Monika BOUET
SCSovy Chao
Sovy Chao
EBEmilie Costa Branquinho
Emilie Costa Branquinho
CBCedric Bouteiller
Cedric Bouteiller
Pierre-Yves RenardPierre-Yves Renard
Pierre-Yves Renard
The two main pathological hallmarks of Alzheimer’s disease (AD) in the brain are senile plaques (SPs) composed of beta-amyloid (Aβ) peptides and neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein. These hallmarks are associated with a cholinergic deficit. While the process leading to the development of AD is complex and multifactorial, and the etiology of AD is not completely known, it is nowadays clear that AD is a multifaceted illness requiring the combination of synergetic treatment strategies. Because definite diagnosis is achieved by postmortem examination of the brain, new noninvasive diagnostic imaging modalities for AD are in high demand, both to detect and monitor the evolution of this sickness, and evaluate the efficacy of treatments. Positron Emission Tomography (PET) is a nuclear molecular imaging technique that uses radiopharmaceuticals labeled with a positron-emitting isotope (carbon-11, fluorine-18, copper-64, gallium- 68…), to visualize in vivo cellular metabolism with high-spatial resolution and unique sensitivity, while Single-Photon Emission Computed Tomography (SPECT) using radioisotopes such as technetium-99m or iodine-123. Besides being a powerful tool for diagnosis (mostly in oncology with [18F]-FDG), PET experiments can provide information about biochemical mechanisms in living tissues or interactions between neurotransmitter and brain receptors. For the past two decades, numerous radiopharmaceuticals have been developed for imaging the lesions observed in AD patients. Tau aggregates and Aβ plaques can also be visualized and quantified by mean of specific radioligands. The latter has been the focus of intense research efforts lately, leading to new FDA approved radiopharmaceuticals. This paper aimed at summarizing the recent advances in PET and SPECT imaging of AD pathophysiology.

1 May 2013 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
EBEmilie Da Costa Branquinho
Emilie Da Costa Branquinho
GBGuillaume Becker
Guillaume Becker
CBCédric Bouteiller
Cédric Bouteiller
Ludovic JeanLudovic Jean
Ludovic Jean
Pierre-Yves RenardPierre-Yves Renard
Pierre-Yves Renard
LZLuc Zimmer
Luc Zimmer

5 August 2021 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
JFJulien Fouque
Julien Fouque
TRTimofei Rusu
Timofei Rusu
SHSamuel Huguet
Samuel Huguet
EBEmilie Da Costa Branquinho
Emilie Da Costa Branquinho
SBSandy Blondeel‐Gomes
Sandy Blondeel‐Gomes
OMOlivier Madar
Olivier Madar